MDxHealth SA (NASDAQ:MDXH) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of MDxHealth SA (NASDAQ:MDXH - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the five ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $7.75.

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of MDxHealth in a research note on Friday, March 27th.

Hedge Funds Weigh In On MDxHealth

Hedge funds have recently modified their holdings of the stock. Intesa Sanpaolo Wealth Management acquired a new position in shares of MDxHealth in the fourth quarter worth $36,000. Lido Advisors LLC bought a new position in MDxHealth during the third quarter valued at about $48,000. GSA Capital Partners LLP bought a new position in MDxHealth during the third quarter valued at about $48,000. Squarepoint Ops LLC bought a new position in MDxHealth during the fourth quarter valued at about $51,000. Finally, Jefferies Financial Group Inc. bought a new position in MDxHealth during the third quarter valued at about $53,000.

MDxHealth Trading Up 1.0%

NASDAQ MDXH opened at $2.02 on Thursday. MDxHealth has a 1-year low of $1.69 and a 1-year high of $5.33. The company has a market capitalization of $99.98 million, a PE ratio of -3.01 and a beta of 1.60. The firm's fifty day simple moving average is $2.67 and its 200-day simple moving average is $3.35.

MDxHealth (NASDAQ:MDXH - Get Free Report) last posted its quarterly earnings results on Friday, February 27th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.04). MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 31.07%.The company had revenue of $29.55 million during the quarter, compared to analyst estimates of $26.05 million. As a group, analysts predict that MDxHealth will post -0.41 EPS for the current year.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth's lead product portfolio includes ConfirmMDx and SelectMDx.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.